Home › Trial NCT05661578
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
- Trial IDNCT05661578
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorHoffmann-La Roche
- Enrollment64
- Start date2023-05-04
- ConditionsPD-L1-selected Solid Tumors
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.